- •Presumed early-stage ovarian carcinoma had lymph node involvement in 8.4% of cases.
- •Histology and grade rather than lymph node status determined the indication of adjuvant chemotherapy.
- •High grade histology was the only variable that negatively impacted disease-free survival in univariate analysis.
Our objective was to analyze the prevalence of lymph node metastasis in early-stage ovarian carcinoma after systematic lymph node dissection and its impact on indication of adjuvant chemotherapy.
We evaluated a series of 765 patients diagnosed with ovarian carcinoma who underwent surgical treatment from February 2007 to December 2019. Patients with peritoneal disease and incomplete surgical staging were excluded. All cases underwent systematic pelvic and para-aortic lymphadenectomy up to the renal vessels.
A total of 142 cases were analyzed. Median pelvic and para-aortic lymph node dissected were 30 (range, 6–81) and 21 (range, 3–86), respectively. Twelve (8.4%) patients had metastatic lymph nodes – high-grade serous, 10.4% (5/48); clear cell, 17.2% (5/29) and endometrioid, 5.7% (2/35). Any other histology (low grade serous, mucinous, carcinosarcoma or mixed) had lymph node metastasis. Notably, 50% of patients with positive lymph nodes had preoperative suspicious lymph nodes in imaging. The median hospital stay length was 6 days (range, 2–33) and 4.2% cases had grade ≥ 3 complications. A total of 110 (77.6%) patients underwent adjuvant chemotherapy and all cases had indication of adjuvant chemotherapy after histological type, despite the lymph node status. After a median follow-up of 52.5 months, we noted 24 (16.9%) recurrences. The 5-year recurrence-free survival and overall survival were 86.4% and 98.1%, respectively. High grade histology was the only variable that negatively impacted disease-free survival in univariate analysis [HR 4.70 (95%CI: 1.09–20); p = 0.037].
We found a positive lymph node rate of less than 10% after lymphadenectomy in presumed early-stage ovarian carcinoma. Lymph node status was not determinant for adjuvant chemotherapy.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Obstetrics and Gynecology and Reproductive Biology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: Report from the fourth ovarian cancer consensus conference.Internat J Gynecol Cancer. 2010; 2011: 750-755
- Clinical research in epithelial ovarian cancer and patients’ outcome.Ann Oncol. 2011; 22: 16-19
- Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer.Internat J Gynecol Cancer. 2007; 17: 1238-1244
- Stage- and histologic subtype-dependent frequency of lymph node metastases in patients with epithelial ovarian cancer undergoing systematic pelvic and paraaortic lymphadenectomy.Ann Surg Oncol. 2018; 25: 2053-2059https://doi.org/10.1245/s10434-018-6412-y
- Sentinel-node biopsy in early-stage ovarian cancer: preliminary results of a prospective multicentre study (SELLY).Am J Obstet Gynecol. 2019; 221: 324.e1-324.e10
- Staging classification for cancer of the ovary, fallopian tube, and peritoneum.Internat J Gynecol Obstet. 2014; 124: 1-5
- How to manage lymph nodes in ovarian cancer.Cancer. 2019; 125: 4573-4577
- A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms.N Engl J Med. 2019; 380: 822-832
- Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey.Ann Surg. 2004; 240: 205-213
- Systematic Pelvic and Paraaortic Lymphadenectomy for Advanced Ovarian Cancer: Prognostic Significance of Node Metastases.Gynecol Oncol. 1996; 62
- Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?.Gynecol Oncol. 2021; 160: 56-63
- Lymph node metastasis in stages i and II ovarian cancer: A review.Gynecol Oncol. 2011; 123: 610-614
- The attributive value of comprehensive surgical staging in clinically early-stage epithelial ovarian carcinoma: A systematic review and meta-analysis.in: Gynecologic Oncology. Vol. 161. Academic Press Inc., 2021: 876-883
- Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis.Br J Cancer. 2006; 95: 699-704
- Lymphadenectomy for primary ovarian cancer: A systematic review and meta-analysis.J Gynecol Oncol. 2020; 31: 1-13
- ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.Ann Oncol. 2019; 30: 672-705
Cancer O. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) NCCN.org NCCN Guidelines for Patients ® available at www.nccn.org/patients [Internet]. 2021. Available from: www.nccn.org/patients.
- Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm-trial.J Natl Cancer Inst. 2003; 95: 113-125
Published online: September 06, 2022
Accepted: August 30, 2022
Received in revised form: June 27, 2022
Received: April 22, 2022
© 2022 Elsevier B.V. All rights reserved.